High-frequency aflibercept injections in persistent neovascular age-related macular degeneration
- 138 Downloads
We would like to address several challenges that have arisen from the study by Muftuoglu et al.  which are specifically summarized below.
Missing data from the article by Muftuoglu et al. 
The baseline characteristics of patients at the time of switching from Q4W bevacizumab/ranibizumab injections to Q8W aflibercept injections
The washout period between the last Q4W bevacizumab/ranibizumab injection and the first Q8W aflibercept injection
Some anatomical lesions of neovascular maculopathy at enrollment and at the end of the follow-up including the type of choroidal neovascularization(occult/minimally classic, predominantly classic), serous and/or hemorrhagic detachment of the neurosensory retina, and retinal hard exudates
Anatomical types of macular edema (diffuse/subretinal fluid/cystic changes within the neurosensory retina/mixed type) at presentation and at month 12
Proportion of the...
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.
The authors have full control over the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.
Compliance with ethical standards
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
- 4.Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMedGoogle Scholar